U.S. Personalized Medicine Biomarkers Market Size & Outlook
U.S. personalized medicine biomarkers market, 2018-2030 (US$M)
Related Markets
U.S. personalized medicine biomarkers market highlights
- The U.S. personalized medicine biomarkers market generated a revenue of USD 4,584.9 million in 2021 and is expected to reach USD 16,117.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 15% from 2022 to 2030.
- In terms of segment, treatment selection was the largest revenue generating application in 2021.
- Early Detection/Screening is the most lucrative application segment registering the fastest growth during the forecast period.
Personalized medicine biomarkers market data book summary
| Market revenue in 2021 | USD 4,584.9 million |
| Market revenue in 2030 | USD 16,117.2 million |
| Growth rate | 15% (CAGR from 2021 to 2030) |
| Largest segment | Treatment selection |
| Fastest growing segment | Early Detection/Screening |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring |
| Key market players worldwide | Labcorp Holdings Inc, Quest Diagnostics Inc, Agilent Technologies Inc, Genome Medical, Coriell Life Sciences, Thermo Fisher Scientific Inc, NeoGenomics, Foundation Medicine, Illumina Inc, Guardant Health Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.0% of the global personalized medicine biomarkers market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. personalized medicine biomarkers market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,472.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Personalized Medicine Biomarkers Market Scope
Personalized Medicine Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. personalized medicine biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to personalized medicine biomarkers market will help companies and investors design strategic landscapes.
Treatment selection was the largest segment with a revenue share of 52.87% in 2024. Horizon Databook has segmented the U.S. personalized medicine biomarkers market based on early detection/screening, diagnosis, treatment selection, monitoring covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. personalized medicine biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. personalized medicine biomarkers market databook
-
Our clientele includes a mix of personalized medicine biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. personalized medicine biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into U.S. personalized medicine biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. personalized medicine biomarkers market report size, by application, 2018-2030 (US$M)
U.S. Personalized Medicine Biomarkers Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
